The United States and United Kingdom Agree to Duty-Free Agreement on Prescription Drugs.

The UK and US have reached a key trade agreement that will maintain zero import taxes on UK drug products going into the US market.

Key Provisions of the Pact

As part of the deal, the UK has pledged to increase expenditure on medicines through the public health system. This move secures that import taxes on these key products will be held at zero for a timeframe of three years.

This agreement comes after recent threats to significantly raise duties on branded pharmaceutical products, with increases floated up to one hundred percent.

"This agreement with the Britain reinforces the global environment for cutting-edge drugs and brings long-overdue fairness to transatlantic medicine commerce," a statement said.

Commercial Importance

Drugs are one of the UK's biggest export categories to the America, which is easily the primary destination for large British pharmaceutical firms.

Trade data show that in the 12 months to the end of last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value made up 17.4% of British export trade in that period.

"This agreement protects employment, increases capital expenditure and facilitates the UK to become a international leader for medical research," a minister remarked.

Specific British Pledges

The agreement includes several key pledges from the United Kingdom:

• Price Threshold Increase: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by twenty-five percent.
• Higher Drug Budget: There is a target to raise total health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
• Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds exceeded 20%.

Broader Context

This agreement comes amid a protracted row between the sector and the UK government over drug pricing and approval rates.

The disagreement were heightened by assertions that American customers were paying a premium for the same drugs than people in the other developed nations.

Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial funding commitments have been announced toward American operations.

The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the past decade.